Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Cohen

Showing results (321-330 of 403) with videos related to

Pageof 41
Sort By:
Current Problems in Cardiology|December 4, 2022
Diversity in U.S. Cardiovascular Trainees and Leadership Where we are and What the Future HoldsChristoph W Sossou, Sadaf Fakhra, Kavita Batra, et al.
Angiology|February 11, 2016
Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention: An Analysis of the Randomized ATOLL TrialZhenyu Liu, Johanne Silvain, Mathieu Kerneis, et al.
Journal of the American College of Cardiology|June 12, 2003
Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registryGregg W Stone, E Magnus Ohman, Michael F Miller, et al.
Journal of the American College of Cardiology|October 3, 2006
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromesMarc Cohen, Kenneth W Mahaffey, Karen Pieper, et al.
The Laryngoscope|April 12, 2018
Long-term outcomes in oral cavity squamous cell carcinoma with adjuvant and salvage radiotherapy after surgeryEvangelia Katsoulakis, Jonathan E Leeman, Benjamin H Lok, et al.
Circulation. Cardiovascular Interventions|June 14, 2018
Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO TrialJean-Guillaume Dillinger, Gregory Ducrocq, Yedid Elbez, et al.
European Heart Journal|June 30, 2007
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysisSabina A Murphy, Charles Michael Gibson, David A Morrow, et al.
The American Journal of Cardiology|April 24, 2017
Meta-Analysis of Randomized Controlled Trials of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Left Main Coronary Artery DiseaseAakash Garg, Sunil V Rao, Sahil Agrawal, et al.
Journal of the American College of Cardiology|April 23, 2013
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51C Michael Gibson, Anjan K Chakrabarti, Jessica Mega, et al.
Journal of the American College of Cardiology|July 29, 2017
Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 TrialElizabeth A Magnuson, Haiyan Li, Kaijun Wang, et al.
Pageof 41

Showing results (321-330 of 403) with videos related to

Sort By:
Pageof 41
Current Problems in Cardiology|December 4, 2022
Diversity in U.S. Cardiovascular Trainees and Leadership Where we are and What the Future HoldsChristoph W Sossou, Sadaf Fakhra, Kavita Batra, et al.
Angiology|February 11, 2016
Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention: An Analysis of the Randomized ATOLL TrialZhenyu Liu, Johanne Silvain, Mathieu Kerneis, et al.
Journal of the American College of Cardiology|June 12, 2003
Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registryGregg W Stone, E Magnus Ohman, Michael F Miller, et al.
Journal of the American College of Cardiology|October 3, 2006
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromesMarc Cohen, Kenneth W Mahaffey, Karen Pieper, et al.
The Laryngoscope|April 12, 2018
Long-term outcomes in oral cavity squamous cell carcinoma with adjuvant and salvage radiotherapy after surgeryEvangelia Katsoulakis, Jonathan E Leeman, Benjamin H Lok, et al.
Circulation. Cardiovascular Interventions|June 14, 2018
Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO TrialJean-Guillaume Dillinger, Gregory Ducrocq, Yedid Elbez, et al.
European Heart Journal|June 30, 2007
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysisSabina A Murphy, Charles Michael Gibson, David A Morrow, et al.
The American Journal of Cardiology|April 24, 2017
Meta-Analysis of Randomized Controlled Trials of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Left Main Coronary Artery DiseaseAakash Garg, Sunil V Rao, Sahil Agrawal, et al.
Journal of the American College of Cardiology|April 23, 2013
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51C Michael Gibson, Anjan K Chakrabarti, Jessica Mega, et al.
Journal of the American College of Cardiology|July 29, 2017
Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 TrialElizabeth A Magnuson, Haiyan Li, Kaijun Wang, et al.
Pageof 41